Please ensure Javascript is enabled for purposes of website accessibility

Where to Invest $10,000 in the Next Market Crash

By Jason Hawthorne - Feb 26, 2021 at 6:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A proven strategy and new growth opportunities will help you sleep at night owning this winner.

One lesson of the March 2020 market crash is that stocks can drop much faster than anyone expects. To take advantage of those opportunities, investors need to do their homework, preparing to buy great companies when short-term gyrations in their stocks offer an attractive price.

At the top of my list for the next crash is Veeva Systems (VEEV 0.87%). The founder-led cloud software provider has been remarkably consistent since going public in 2013. The company has continuously offered new applications to solve more of its customers' problems and is now stretching beyond the life sciences industry, dramatically expanding its addressable market. 

A female researcher in a lab in front of a microscope and computer screen with an image.

Image source: Getty Images.

Solving problems for customers

Veeva Systems was founded on the idea that cloud software would become more industry-specific as it matured. With two co-founders, one from Silicon Valley and the other a life sciences veteran, it made sense to build an application to help biotech and pharmaceutical companies market their products.

That simple idea has led the company to develop many more applications grouped into two packages: the Veeva Commercial Cloud and Veeva Vault. Each of these applications helps life sciences companies navigate the end-to-end drug development process efficiently.

The Commercial Cloud combines customer data, artificial intelligence, and a personalized customer experience to increase stakeholder engagement. What began as a tool to manage customer relationships has grown into a hub for customer and patient data and a suite of analytics tools to plan and execute marketing and sales strategies, as well as to create and distribute content for medical, legal, and regulatory reviews.

Vault, meanwhile, is designed for managing content and data to streamline workflow around regulatory, safety, quality, medical, and commercial tasks. The result is accelerated clinical trials thanks to centralized content, data, and communications. Vault helps drugmakers launch and manage studies, report adverse events, comply with regulatory standards, register products, and submit results.

Reliable results

The consistently impressive growth in Veeva's customers and revenue is a testament to the company's success in creating an industry-specific product. Not only is the number of customers growing, but customer spending has also increased every year. That's a sign that as the company develops new applications, existing customers are eager to pay for the added capabilities because they solve other problems. There is no reason this strategy can't be repeated in other industries.

For Year Ending Jan. 31 Customers Revenue YOY Revenue Growth Revenue per Customer
2020 861 $1.1 billion 28% $1.28 million
2019 719 $860 million 25% $1.20 million
2018 625 $690 million 25% $1.10 million
2017 517 $550 million 35% $1.06 million
2016 400 $410 million 31% $1.02 million

Data source: Veeva Systems. YOY = year over year. 

When Veeva reported its third-quarter earnings, management offered guidance for the full year ending Jan. 31, 2021, of $1.45 billion. That's a 31% year-over-year rise, indicating that the 14-year-old company is accelerating its growth. And management has a plan to keep the business from slowing down anytime soon.

Expanding the addressable market

Veeva has more ways to grow than just developing new applications for its life science customers. The company has recently been marketing its applications to the consumer goods and cosmetics industries. Much like drug developers, these highly regulated businesses must bring their products to market through a rigorous testing process that requires a lot of data to track and report results. 

Aside from mentioning individual wins on earnings calls, management hasn't broken out the number of customers or amount of revenue generated from new industries. It has noted that the sales cycle is long and that it's difficult to beat an incumbent software application. Comments like that could frustrate investors looking for the hypergrowth of newer cloud software companies. But patient shareholders should view the steady penetration of a new industry as proof that Veeva can sustain its growth rate far into the future. 

An investment that lets you sleep at night

Veeva Systems has a history of impressive growth thanks to its ability to introduce new applications to solve an increasing number of problems in the end-to-end workflows for its life sciences customers. With both the number of customers and the average spend per customer growing annually, it's clearly in touch with customer needs.

As the company moves into the similarly regulated consumer goods and cosmetics industries, expect the growth and innovation to continue, and the valuation to remain stretched. Great businesses are often priced at a premium, and Veeva is no exception. The current price-to-sales (P/S) ratio is 34, near its high of the past five years. But over that time the market has realized the quality of the business. The lowest P/S during the March 2020 sell-off was 20, double what the ratio averaged in 2016.

If that is any indication, this business may never be considered cheap again. Patient investors shouldn't be too picky about valuation during the next marketwide sell-off. Shares of Veeva Systems are likely to reward them over the long term. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Veeva Systems Inc. Stock Quote
Veeva Systems Inc.
VEEV
$163.68 (0.87%) $1.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.